Leerink Swann Reiterates an 'Outperform' on Jazz Pharmaceuticals (JAZZ); Xyrem Patent Strengthens
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Notable Analyst Rating Changes 09/11: (BMY) (SYNC) (JAZZ) Upgraded; (SIRI) (TIBX) (GNOM) Downgraded
September 11, 2012 10:37 AM EDTUPGRADES
Goldman Sachs upgrades Bristol-Myers Squibb Co. (NYSE: BMY) from Buy to Conviction Buy, moving its price target from $38 to $40.... More
Cowen Upgrades Jazz Pharmaceuticals (JAZZ) to Outperform
September 11, 2012 9:51 AM EDTCowen upgraded Jazz Pharmaceuticals (NASDAQ: JAZZ) from Neutral to Outperform.
For an analyst ratings summary and ratings history on Jazz Pharmaceuticals click here. For more ratings news on Jazz Pharmaceuticals click here.
Shares of Jazz Pharmaceuticals closed at $43.56 yesterday, with a 52 week range of $34.02-$54.50.... More
Jazz Pharma (JAZZ) Receives New US Patent for Xyrem; Will Submit to FDA's Orange Book
September 11, 2012 7:40 AM EDTJazz Pharmaceuticals plc. (Nasdaq: JAZZ) announced that a new patent related to Xyrem (sodium oxybate) oral solution titled "Microbiologically Sound and Stable Solutions of Gamma-Hydroxybutyrate Salt for the Treatment of Narcolepsy" will issue today. The new patent, number 8,262,650, will be submitted for listing in... More
